ENDOGENOUS STEROIDS AND CANCER OF THE OVARY

内源性类固醇与卵巢癌

• 批准号: 6377116
• 负责人: Paolo G. Toniolo
• 金额: $ 17.92万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-01 至 2003-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6377116
• 关键词: androstenedione; cancer risk; clinical research; disease /disorder etiology; female; hormone binding protein; hormone regulation /control mechanism; hormone related neoplasm /cancer; human data; human tissue; meta analysis; neoplasm /cancer epidemiology; ovary neoplasms; postmenopause; testosterone; women's health

This proposal is Component 1 of a group of 3 Investigator- Initiated Research Project Grants (IRPG) that are submitted concurrently. The three projects address complementary aspects of the role of endogenous hormones in the etiology of the most common cancers specific to women-ovary, endometrium and breast. All studies are based on the same underlying population, obtained by combining three prospective cohort studies that are under way in New York, Umea (Sweden) and Milan (Italy). The present proposal addresses the potential role of a hyperandrogenic steroid profile in ovarian cancer. The second proposal focuses on hyperandrogenism and estrogens in endometrial cancer and the third (Component 3) on insulin IGF-I as the common determinant of hyperandrogenism in ovarian and endometrial cancers, and in breast cancer in young women. The study seeks to evaluate the hypothesis that the risk of epithelial ovarian cancer is increased in women who experience excessive ovarian androgen production, either as an etiologic factor per se, or as a reflection of chronic ovarian over- stimulation by gonadotropins. The primary aim is to determine whether pre-diagnostic blood levels of the major androgens of ovarian stromal origin, androstenedione and testosterone, are positively associated with the risk of epithelial ovarian cancer in both premenopausal and postmenopausal women. Secondary aim is to show that pre-diagnostic blood levels of SHBG are negatively associated with ovarian cancer in both premenopausal and postmenopausal women. A case-control study (approximately 143 cases and 286 controls) will be nested within the three joint cohort studies. Cases will be women diagnosed with epithelial ovarian cancer after entering any of the three cohort studies. Controls will be women randomly selected from among all eligible individuals from the same cohorts and matching a given case on specified criteria. The study duration will be three years.

该提案是同时提交的 3 项研究者发起的研究项目补助金 (IRRPG) 中的第 1 部分。这三个项目致力于解决内源性激素在女性特有的最常见癌症（卵巢癌、子宫内膜癌和乳腺癌）病因学中的互补作用。所有研究均基于相同的基础人群，通过结合纽约、于默奥（瑞典）和米兰（意大利）正在进行的三项前瞻性队列研究而获得。本提案讨论了高雄激素类固醇在卵巢癌中的潜在作用。第二项提案侧重于子宫内膜癌中的高雄激素血症和雌激素，第三项（组成部分 3）关注胰岛素 IGF-I，它是卵巢癌、子宫内膜癌以及年轻女性乳腺癌中雄激素过多症的共同决定因素。该研究旨在评估以下假设：卵巢雄激素产生过多的女性患上皮性卵巢癌的风险会增加，这要么是其本身的病因，要么是促性腺激素慢性卵巢过度刺激的反映。主要目的是确定卵巢基质来源的主要雄激素（雄烯二酮和睾酮）的诊断前血液水平是否与绝经前和绝经后女性患上皮性卵巢癌的风险呈正相关。次要目的是证明绝经前和绝经后女性的诊断前血液 SHBG 水平与卵巢癌呈负相关。病例对照研究（约 143 例病例和 286 例对照）将嵌套在三个联合队列研究中。病例将是在进入这三项队列研究中的任何一项后被诊断患有上皮性卵巢癌的女性。对照将是从同一队列的所有符合条件的个体中随机选出的女性，并根据指定标准匹配给定病例。学习期限为三年。